Anna Mazurkiewicz-Pisarek PhD Eng.

Specialist in area of recombinant proteins production in procaryotic expression systems. In 2003 graduated from Warsaw University of Technology, Faculty of Chemical and Process Engineering, MSc in the field of industrial biotechnology. In 2017 she defended PhD thesis in the field of biocybernetics and biomedical engineering at the Institute of Biocybernetics and Biomedical Engineering Polish Academy of Science. She has worked at Institute of Biotechnology and Antibiotics for 16 years gaining experience in biotechnology including genetic engineering, recombinant protein isolation and purification. In 2020 she joined Technology Centre for Advanced Materials and Technologies of Warsaw University of Technology as Assistant Professor. Author and co-author of 4 patents, 10 publications and over 30 posters in international scientific conferences. Leader and participant of multiple scientific projects related to obtaining of new forms of a biological active proteins, construction of expression vectors, isolation and purification of recombinant proteins and cell cultures in laboratory and quarter-technical scale (contoxins, blood coagulation factors, interferons, growth hormone).

Founder and CEO of the BioTech Startup Science4Beauty Ltd. that was awarded by European Funding Grant worth 1M Euro from National Center of Research and Development POIR 3_2020.

• Wojtowicz A., Mazurkiewicz-Pisarek A., Płucienniczak A., et al., ,,Expression of yeast deubiquitination enzyme UBP1 analogues in E. coli”. Microbial Cell Factories, 2005, 4-17, 2005.
• Mazurkiewicz A., Matuszewska A., Molenda J., ,,Mechanizm powstawania wielopierścieniowych węglowodorów aromatycznych w mineralnych olejach silnikowych”. Problemy eksploatacji 46, 167 –178, 2002.
• Wojtowicz A., Mazurkiewicz-Pisarek A., Płucienniczak A. ,,Using of recombinant deubiquitinating enzyme (UBP1) analogues for processing of fusion proteins obtained in Escherichia coli”, Acta Bioch. Polonica 52, 2005.
• Mazurkiewicz-Pisarek A., Płucienniczak A., ,,Toksyna botulinowa – wonderful poison”. Biotechnologia, 2(85), 2009.
• Mazurkiewicz-Pisarek A., ,,Synthetic construction of FVIII gene and expression in CHO-dhfr cells”, Febs Journal 278, 117-118, 2011.
• Wojtowicz-Krawiec A., Mazurkiewicz-Pisarek A., et al., ,,The RepRS, RepRS2 and RepMSS proteins in the specyfic DNA binding activity” Febs Journal 278, 133, 2011.
• Mazurkiewicz-Pisarek A., et al., ,,Cloning, expression in CHO-dhfr cells and purification of the 6-histag blood coagulation factor”, New Biotechnology (29), 116, 2012. doi:10.1016/j.nbt.2012.08.323
• Wójtowicz A., Mazurkiewicz-Pisarek A., Płucienniczak G., et al., ,,Use of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli”. Microbial Cell Factories, 2014. doi: 10.1186/s12934-014-0113-4.
• Mazurkiewicz-Pisarek A., Ciach T., Płucienniczak G., Płucienniczak A., ,,The factor VIII protein and its function”, Acta Bioch. Polonica 63(1), 11-16, 2016. doi:10.18388/abp.2015_1056.
• Wawrzyniak P., Sobolewska- Ruta A., Lukasiewicz N., Kabaj P., Kierył P., Baran P., Bierczyńska-Krzysik A., Maurkiewicz-Pisarek A., Plucienniczak A. and Bartosik D, ,,Molecular dissection of the replication system of plasmid pIGRK encoding two in-frame Rep proteins with antagonistis functions”, BMC Microbiology, 2019, doi:10.1186/s12866-019-1595-3.

1. Wójtowicz A., Mazurkiewicz-Pisarek A., Chojnacka L., Płucienniczak A. UBP1 protease mutant, and its coding sequence, their applications and heterogonous protein expression system. US 8158382 B2, 17.04.2012.
2. Wójtowicz A., Mazurkiewicz-Pisarek A., Chojnacka L., Płucienniczak A. UBP1 protease mutant, and its coding sequence, their applications and heterogonous protein expression system. EP1841862B1, 06.03.2013.
3. Płucienniczak A., Płucienniczak G., Mazurkiewicz-Pisarek A., et al. “Method for production of recombinant growth hormone in form of hybrid protein”. US7892787 B1, 02.2011.
4. Płucienniczak A., Płucienniczak G., Mazurkiewicz-Pisarek A., et al. “Method for production of recombinant growth hormone in form of hybrid protein”. EP1706494B1; 04.07.2012.